Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Lance Baldo Biography and Net Worth

Insider of Adaptive Biotechnologies

Dr. Lance Baldo is Chief Medical Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Before joining Adaptive, Lance served in various roles of ascending responsibility with the Roche Group and its affiliates from February 2010 to April 2019, including most recently as Senior Vice President and Head of U.S. Medical Affairs of Genentech. Prior to joining the Roche Group, Lance served as Vice President, Global Medical Science and Affairs at The Medicines Company, a public biopharmaceuticals company, from September 2005 to February 2010. Lance also founded a medical software company, MedAptus which was later acquired by the Volaris Group.

Lance serves on the Board of Advisors for the Werth Institute for Entrepreneurship and Innovation at the University of Connecticut, advising the school and young entrepreneurs with promising ideas for potential commercial development. Lance also supports Johns Hopkins Technology Ventures by helping assess promising university research, enabling discoveries to move from bench to the bedside. Lance holds an MD from the University of Connecticut School of Medicine and a BA in Biology from Johns Hopkins University.

What is Lance Baldo's net worth?: The estimated net worth of Lance Baldo is at least $255,200.00 as of January 27th, 2021. Dr. Baldo owns 40,000 shares of Adaptive Biotechnologies stock worth more than $255,200 as of December 3rd. This net worth approximation does not reflect any other assets that Dr. Baldo may own. Learn More about Lance Baldo's net worth.
How do I contact Lance Baldo?: The corporate mailing address for Dr. Baldo and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Lance Baldo's contact information.
Has Lance Baldo been buying or selling shares of Adaptive Biotechnologies?: Lance Baldo has not been actively trading shares of Adaptive Biotechnologies during the past quarter. Most recently, Lance Baldo sold 2,373 shares of the business's stock in a transaction on Monday, March 7th. The shares were sold at an average price of $12.01, for a transaction totalling $28,499.73. Learn More on Lance Baldo's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

Lance Baldo Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2022	Sell	2,373	$12.01	$28,499.73
1/27/2021	Sell	40,000	$58.95	$2,358,000.00	40,000
12/7/2020	Sell	6,250	$50.41	$315,062.50	6,250
10/6/2020	Sell	6,250	$49.20	$307,500.00	6,250
9/29/2020	Sell	25,000	$50.00	$1,250,000.00	25,000
9/11/2020	Sell	4,149	$40.00	$165,960.00	18
9/8/2020	Sell	2,083	$36.17	$75,342.11	2,083
8/6/2020	Sell	6,250	$40.00	$250,000.00	6,250
7/6/2020	Sell	6,250	$47.33	$295,812.50	6,250
6/9/2020	Sell	6,250	$43.73	$273,312.50	2,083
5/6/2020	Sell	50,000	$33.86	$1,693,000.00	50,000

Lance Baldo Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $6.38

$6.16

$6.55

50 Day Range

MA: $5.12

$4.00

$6.53

2 Week Range

Now: $6.38

$2.28

$6.70

Volume

340,154 shs

Average Volume

1,418,472 shs

Market Capitalization

$941.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49